Finally, the court held that the corporate defendant’s misappropriation was an actionable harm, despite not launching a competing product, because plaintiff “lost the exclusive use of trade secret information, which is a real and redressable harm,” and the misappropriation provides the corporate defendant “a jumpstart to an industry it would otherwise not have competitively joined for another decade. [read post]